← All trials
NCT00344149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2006
- Primary completion
- Mar 1, 2014
- Completion date
- Mar 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Ostfold UniversityLead sponsor
- Osaka UniversityOverall official - principal investigator
- University of StavangerOverall official - principal investigator
- Norwegian University of Science and TechnologyOverall official - principal investigator
- Osaka UniversityCollaborator
- South-Eastern Norway Regional Health AuthorityCollaborator
- Ostfold UniversityReponsible party - principal investigator
- University of OsloOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.